Your browser is no longer supported. Please, upgrade your browser.
Settings
PIRS Pieris Pharmaceuticals, Inc. daily Stock Chart
PIRS [NASD]
Pieris Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.55 Insider Own30.00% Shs Outstand44.16M Perf Week-3.69%
Market Cap103.78M Forward P/E- EPS next Y-0.58 Insider Trans0.00% Shs Float41.10M Perf Month-15.47%
Income-22.80M PEG- EPS next Q0.16 Inst Own46.90% Short Float1.68% Perf Quarter16.92%
Sales5.80M P/S17.89 EPS this Y-33.70% Inst Trans0.07% Short Ratio2.65 Perf Half Y46.87%
Book/sh0.59 P/B3.98 EPS next Y-45.00% ROA-56.10% Target Price9.00 Perf Year6.82%
Cash/sh0.67 P/C3.53 EPS next 5Y- ROE-75.30% 52W Range1.30 - 3.09 Perf YTD67.26%
Dividend- P/FCF- EPS past 5Y- ROI-91.00% 52W High-23.95% Beta-
Dividend %- Quick Ratio3.90 Sales past 5Y- Gross Margin- 52W Low80.77% ATR0.15
Employees49 Current Ratio3.90 Sales Q/Q28.60% Oper. Margin- RSI (14)48.00 Volatility6.15% 5.87%
OptionableNo Debt/Eq0.00 EPS Q/Q-109.00% Profit Margin- Rel Volume0.19 Prev Close2.35
ShortableYes LT Debt/Eq0.00 EarningsMar 22 AMC Payout- Avg Volume260.47K Price2.35
Recom1.50 SMA20-3.73% SMA50-3.26% SMA20026.43% Volume48,335 Change0.00%
Aug-05-16Resumed ROTH Capital Buy
Aug-12-15Initiated JMP Securities Mkt Outperform
Jul-27-15Initiated Oppenheimer Outperform $8
Jul-22-15Initiated ROTH Capital Buy $7
Apr-04-17 07:30AM  Pieris Pharmaceuticals Presents IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, in Poster Session at the 2017 Meeting of the American Association for Cancer Research (AACR)
Mar-31-17 01:36PM  Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017
10:40AM  Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: 2016 By the Numbers : March 31, 2017
Mar-30-17 06:04AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Mar-23-17 06:04AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
Mar-22-17 08:18PM  Pieris Pharmaceuticals Reports Full-Year 2016 Financial Results and Corporate Update Marketwired
08:36AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-15-17 07:30AM  Pieris Pharmaceuticals to Host Full-Year 2016 Investor Call And Corporate Update on March 23, 2017 Marketwired
Mar-14-17 07:30AM  Pieris Pharmaceuticals to Present at Oppenheimer's 27th Annual Healthcare Conference, Wednesday, March 22nd at 11:30 am EDT Marketwired
Mar-07-17 07:30AM  Pieris Pharmaceuticals to Present at the 29th Annual Roth Conference Monday, March 13th at 2:00 pm PST Marketwired
Mar-06-17 07:30AM  Pieris Pharmaceuticals Announces Presentation of IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2017 Meeting of the American Association for Cancer Research (AACR) Marketwired +18.92%
Mar-01-17 08:00AM  Pieris Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6th at 4:40 pm EST Marketwired
Feb-27-17 08:22AM  Pieris Pharmaceuticals' stock soars after exclusive license deal with Japan's ASKA at MarketWatch +5.21%
07:30AM  Pieris Signs 1st Partnership for Anemia Drug PRS-080, Granting Exclusive Option in Japan to ASKA Pharmaceutical Marketwired
Feb-08-17 07:30AM  Pieris Pharmaceuticals to Present at the Bio CEO Investor Conference on February 13th at 1:30 pm EST Marketwired
Feb-07-17 05:22PM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Change in Directors
05:21PM  Pieris Announces Management Transition Marketwired
Jan-09-17 06:08AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-05-17 07:30AM  Pieris Pharmaceuticals to Host Investor Call Today to Discuss Servier Collaboration Marketwired +19.73%
07:06AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
07:00AM  Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance Marketwired
Dec-16-16 10:11PM  What Hedge Fund Sentiment Says About Pieris Pharmaceuticals Inc (PIRS) And Its Peers at Insider Monkey
Dec-01-16 08:00AM  Pieris Pharmaceuticals Appoints Claude Knopf as Chief Business Officer Marketwired
Nov-18-16 01:04PM  PIERIS PHARMACEUTICALS, INC. Financials
Nov-11-16 11:31AM  Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016
Nov-10-16 08:32AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
Nov-09-16 06:01PM  Pieris Pharmaceuticals reports 3Q loss +7.14%
05:50PM  Pieris Pharmaceuticals Reports Financial Results and Provides Corporate Update for the Third Quarter Ended September 30, 2016 Marketwired
Nov-01-16 08:00AM  Pieris Pharmaceuticals to Host Third Quarter 2016 Investor Call and Corporate Update on November 10, 2016 Marketwired
Oct-26-16 08:00AM  Pieris Pharmaceuticals to Receive GLP Tox Milestone Payment in Daiichi Sankyo Collaboration Marketwired
Oct-24-16 07:59AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Oct-20-16 08:00AM  Pieris Announces Presentations at Upcoming R&D Conferences Marketwired
Oct-05-16 05:27PM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
Sep-28-16 10:30AM  PIRS: Positive Preclinical Data Presented for PRS-343
Sep-26-16 05:15PM  Pieris Pharmaceuticals Presents Positive Data for Its Lead Bispecific Drug Candidate, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Marketwired
Sep-22-16 10:26AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and +5.03%
08:00AM  Pieris Pharmaceuticals Appoints Christopher Kiritsy to Its Board of Directors Marketwired
Sep-07-16 08:30AM  Pieris Pharmaceuticals Announces Presentation of Data for Its Lead IO Bispecific Program, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Marketwired
Sep-01-16 10:31AM  Pieris Pharmaceuticals to Present at Rodman & Renshaw 18th Annual Global Investor Conference Marketwired
Aug-12-16 04:00PM  PIRS: Development of Multiple Anticalin® Products Continues
11:22AM  Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
Aug-11-16 09:26AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
Aug-10-16 05:05PM  Pieris Pharmaceuticals reports 2Q loss
05:00PM  Pieris Pharmaceuticals Reports Financial Results and Provides Corporate Update for the Second Quarter Ended June 30, 2016 Marketwired
Aug-01-16 08:00AM  Pieris Pharmaceuticals to Host Second Quarter 2016 Investor Call and Corporate Update on August 11, 2016 Marketwired
Jul-26-16 09:23AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
08:00AM  Pieris Pharmaceuticals Appoints Julian Adams, Ph.D., to Its Board of Directors Marketwired
Jul-14-16 11:58AM  5 Stocks Under $10 Set to Soar
Jul-01-16 08:49AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to
Jun-14-16 07:59AM  Pieris Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences Marketwired
Jun-09-16 05:23PM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events -5.43%
Jun-08-16 05:02PM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
11:20AM  Pieris Pharmaceuticals Announces Closing of $16.5 Million Private Placement Marketwired
Jun-06-16 08:01AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Jun-03-16 09:00AM  Pieris Pharmaceuticals Announces $16.5 Million Private Placement Marketwired
Jun-01-16 03:22PM  Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016
May-19-16 11:39AM  5 Stocks Under $10 Set to Soar
May-18-16 03:30PM  PIRS: PRS-343 Shows Efficacy in Humanized Mouse Cancer Model
May-12-16 09:41AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -5.61%
May-11-16 05:04PM  Pieris Pharmaceuticals reports 1Q loss
05:00PM  Pieris Pharmaceuticals Reports Financial Results and Corporate Update for the First Quarter Ended March 31, 2016 Marketwired
Apr-27-16 08:00AM  Pieris Pharmaceuticals to Host First Quarter 2016 Investor Call and Corporate Update on May 12, 2016 Marketwired -6.82%
Apr-18-16 07:06AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Apr-07-16 04:17PM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements
Mar-29-16 04:40PM  PIRS: In Vivo Preclinical Data on PRS-343 to be Presented at AACR 2016
Mar-28-16 11:50AM  Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q4, 2015 By the Numbers
Mar-24-16 12:11PM  Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: 2015 By the Numbers +9.66%
Mar-23-16 09:28AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -6.38%
Mar-22-16 04:18PM  Pieris Pharmaceuticals reports 4Q loss
04:05PM  Pieris Pharmaceuticals Reports Full-Year 2015 Financial Results and Corporate Update Marketwired
Mar-17-16 08:00AM  Pieris Pharmaceuticals Announces Presentation of In Vivo Preclinical Data for Its Lead Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2016 Annual Meeting of the American Association for Cancer Research (AACR) Marketwired
Mar-03-16 08:00AM  Pieris Pharmaceuticals to Host Full-Year 2015 Investor Call and Corporate Update on March 23, 2016 Marketwired
Mar-02-16 08:00AM  Pieris Pharmaceuticals to Present at the Cowen & Company 36th Annual Healthcare Conference on March 9th at 10:00 am ET Marketwired
Feb-29-16 08:55AM  Pieris Pharmaceuticals to Present at the 28th Annual ROTH Conference on March 15th at 10:30 am PDT Marketwired
Feb-17-16 02:30PM  PIRS: Owner of an Entire Drug Class That is Safe, Differentiated, and Complementary to Current Treatments +6.92%
Jan-28-16 08:30AM  Pieris Pharmaceuticals to Present at the 18th Annual BIO CEO and Investor Conference on February 8th at 9:30 am ET Marketwired +8.43%
Jan-11-16 09:03AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Dec-22-15 09:00AM  The Life Sciences Report Announces 19 Companies for the 2016 Small-Cap Biotech Watchlist Marketwired
Dec-14-15 01:38PM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
10:23AM  Biotech stocks with Ground-Breaking Potential Accesswire
Dec-08-15 01:38PM  4 Small Cap NASDAQ/NYSE Stocks to Watch Today Accesswire +35.44%
08:32AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
07:30AM  Pieris Pharmaceuticals Announces First Cancer Immunotherapy Collaboration Marketwired
Dec-07-15 09:07AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -12.34%
09:00AM  Pieris Pharmaceuticals Presents Clinical Data for Its Hepcidin Antagonist Program, PRS-080, at the 2015 American Society of Hematology (Ash) Annual Meeting Marketwired
Dec-02-15 12:05PM  PIRS: Attains Favorable Ruling in Arbitration with TUM; Continued Positive Developments from Collaborations
Dec-01-15 09:24AM  Pieris Pharmaceuticals to Present at the Oppenheimer 26th Annual Healthcare Conference on December 8th at 3:55 pm EST Marketwired
Nov-30-15 08:00AM  Pieris Pharmaceuticals Achieves Payment Milestone in Sanofi Collaboration Marketwired
Nov-25-15 06:09AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events +5.53%
Nov-24-15 08:00AM  Pieris Pharmaceuticals CEO to Present at the LD Micro Main Event on December 3rd Marketwired
Nov-20-15 08:09AM  PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Nov-19-15 08:00AM  Pieris Pharmaceuticals Collaborator Daiichi Sankyo Doses First Subject in a Phase 1 Clinical Study for Lead Partnered Anticalin Program Marketwired
Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. The company develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on the development of three drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; and PRS-343, a bispecific protein for oncology diseases. The company has collaboration agreements with Allergan, Inc.; Daiichi Sankyo Company Limited; Sanofi Group; Cadila Healthcare Limited (Zydus Cadila); Strides Arcolab Limited; and F.HoffmannLa Roche Ltd. It also has a strategic alliance with Servier Forge for the co-development of immuno-oncology. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.